CME sets 2027 CEO handover to Lynne Fitzpatrick

CME Group has set out a long-dated leadership transition, announcing on June 17, 2026 that Chairman and Chief Executive Officer Terry Duffy will move to the role of Executive Chairman. Lynne C. Fitzpatrick, currently President and Chief Financial Officer, has been appointed to succeed him as Chief Executive Officer under a plan approved by the Board of Directors.

The transition will become effective on the later of March 1, 2027 and the date on which the company files its Annual Report on Form 10‑K for 2026. Until that transition date, Duffy will continue to serve as Chief Executive Officer, providing continuity in the top leadership role while the company prepares for the handover.

Once the transition date is reached, Duffy will step into the position of Executive Chairman and is scheduled to serve in that capacity through December 31, 2027. The company has put in place formal agreements covering his transition to the new role as part of the succession framework.

Lynne Fitzpatrick will assume the role of Chief Executive Officer on the transition date, taking over operational leadership of CME Group. In addition to becoming CEO, she will join the company’s Board of Directors and its executive committee, expanding her responsibilities from finance and operations to full corporate oversight.

Fitzpatrick is an internal appointee who joined CME Group in 2006 and has served in senior finance and leadership positions. She became Chief Financial Officer in 2023 and has held the combined role of President and CFO since 2024, experience that the company has highlighted in conjunction with the succession announcement.

In connection with the leadership change, the company has furnished an employment agreement for Fitzpatrick that governs her position as Chief Executive Officer. This agreement complements the separate transition and Executive Chairman agreement prepared for Duffy, signaling a structured approach to the upcoming shift.

CME Group stated that its Board of Directors approved the leadership transition plan on June 16, 2026. The board’s decision sets out a defined timetable for the change at the top of the organization while keeping Duffy in senior roles through the end of 2027.

When Fitzpatrick becomes CEO, her addition to the Board of Directors and its executive committee is intended to integrate the chief executive role into CME Group’s governance structure. The combination of executive and board responsibilities will place her at the center of strategic and operational decision-making.

CME Group shares moved lower in trading following the June 17 announcement of the leadership transition. In morning and premarket activity that day, the stock was down about 4%, reflecting an immediate negative market reaction to the succession news.

The announcement was disseminated through a company press release and related regulatory disclosures outlining the transition timeline, board approval, and executive agreements. News outlets highlighted both the handover plan and the share price move as investors responded to the planned change in long-standing leadership.